Navigation Links
Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
Date:11/12/2007

ww.trubion.com" target="_new">http://www.trubion.com.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's ability to successfully conduct clinical trials for TRU-015, TRU-016 and other SMIP(TM) product candidates, the uncertainty of the FDA approval process and other regulatory requirements, the therapeutic and commercial value of Trubion's drug candidates, the company's Wyeth collaboration, including its ability to receive milestone payments from Wyeth, and risks associated with defending and enforcing any patent claims or other intellectual property rights; and such other risks as identified in the company's quarterly report on Form 10-Q for the period ended September 30, 2007, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate website at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

TRBN-G

Contact:

Jim DeNike<
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015 ... Research abre hoy su llamada a nominaciones para 2015. ... científica ha hecho, o tiene el potencial para hacer, ... Las nominaciones se aceptarán hasta el 15 de marzo ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), a ... today that the Company closed its previously announced ... Jack W. Schuler , Birchview Fund LLC ... million, before offering expenses.  The proceeds will be ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... the first Wisconsin governor elected to four consecutive terms, and ... governor to be tagged with radio frequency identification for digital ... Thompson, who also served as Secretary of Health and ... of the security technology firm Applied Digital's VeriChip ...
... Madison, Wis. - The Wisconsin Alumni Research Foundation ... Chemicon to commercialize research products using WARF's stem ... Tuesday. , ,Chemicon will have non-exclusive access to WARF's ... patented through the University of Wisconsin-Madison . ...
... Technologies of suburban Madison has received a Phase ... from the National Cancer Institute. The grant is to ... of protein activity, useful for cancer research. , ,Last ... grant for $2.14 million from the National Institute for ...
Cached Biology Technology:Tommy Thompson to get RFID implant 2Tommy Thompson to get RFID implant 3WARF signs stem cell agreement with California firm 2
(Date:12/11/2014)... Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... addition of the "Biometrics Market in the APAC ... One major trend emerging in this market is advances ... important to upgrade biometric solutions to the latest standard ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ...
(Date:12/10/2014)... Baptist Medical Center today announced plans for a new medical ... $50 million capital project is part of a larger capital ... The medical education building will be located in the ... 525@vine in Wake Forest Innovation Quarter. Construction will begin immediately ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... of healthcare stakeholders address questions related to health ... disparities in a two-day invitational roundtable on March ... Health Policy, the Agency for Healthcare Research and ... Participants represent the perspectives and concerns of community ...
... Improved environmental conditions have enabled the otter ( Lutra ... years. However, the recovery of populations of this mammal has ... human activities still prevents the species from gaining a foothold. ... acts as a strong impediment to the expansion of the ...
... only a structural support protein in the microenvironment of breast ... However, laminin is far more than just a ... one of the world,s foremost breast cancer scientists have shown ... breast cancer, ,the second most common cancer and second leading ...
Cached Biology News:HIT's impact on health disparities: Will it help or harm? 2Otters on road to recovery in Andalusia 2Berkeley Lab researchers illuminate laminin's role in cancer formation 2Berkeley Lab researchers illuminate laminin's role in cancer formation 3Berkeley Lab researchers illuminate laminin's role in cancer formation 4Berkeley Lab researchers illuminate laminin's role in cancer formation 5
DTT, 25g...
...
...
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
Biology Products: